Emergent Biosolutions (NYSE:EBS) had its price objective boosted by Chardan Capital from $47.00 to $53.00 in a research note issued to investors on Tuesday morning. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on EBS. Wells Fargo & Co reiterated an outperform rating and set a $43.00 target price (up previously from $41.00) on shares of Emergent Biosolutions in a research report on Saturday, September 30th. Zacks Investment Research upgraded Emergent Biosolutions from a hold rating to a buy rating and set a $45.00 target price on the stock in a research report on Wednesday, October 25th.

Emergent Biosolutions (EBS) traded up $1.59 on Tuesday, hitting $51.19. The stock had a trading volume of 363,681 shares, compared to its average volume of 265,707. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.37 and a quick ratio of 6.46. Emergent Biosolutions has a twelve month low of $27.94 and a twelve month high of $51.25. The firm has a market capitalization of $2,450.51, a PE ratio of 30.29, a P/E/G ratio of 1.01 and a beta of 1.25.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The business had revenue of $149.43 million for the quarter, compared to analysts’ expectations of $124.55 million. During the same quarter in the previous year, the firm earned $0.56 earnings per share. The business’s revenue was up 4.6% compared to the same quarter last year. equities research analysts forecast that Emergent Biosolutions will post 1.7 earnings per share for the current fiscal year.

In related news, Director Ronald Richard sold 23,681 shares of the business’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $45.02, for a total value of $1,066,118.62. Following the transaction, the director now owns 47,091 shares in the company, valued at approximately $2,120,036.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel Abdun-Nabi sold 21,906 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $47.91, for a total value of $1,049,516.46. Following the completion of the transaction, the chief executive officer now owns 226,040 shares in the company, valued at approximately $10,829,576.40. The disclosure for this sale can be found here. Insiders have sold 206,329 shares of company stock worth $8,892,362 in the last quarter. Insiders own 16.50% of the company’s stock.

A number of hedge funds have recently modified their holdings of EBS. Northern Trust Corp increased its position in Emergent Biosolutions by 47.2% in the 2nd quarter. Northern Trust Corp now owns 906,731 shares of the biopharmaceutical company’s stock valued at $30,747,000 after acquiring an additional 290,863 shares during the period. Dimensional Fund Advisors LP increased its position in Emergent Biosolutions by 7.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,205,712 shares of the biopharmaceutical company’s stock valued at $74,795,000 after acquiring an additional 152,029 shares during the period. Peregrine Capital Management LLC increased its position in Emergent Biosolutions by 40.8% in the 3rd quarter. Peregrine Capital Management LLC now owns 454,857 shares of the biopharmaceutical company’s stock valued at $18,399,000 after acquiring an additional 131,692 shares during the period. Renaissance Technologies LLC increased its position in Emergent Biosolutions by 16.7% in the 2nd quarter. Renaissance Technologies LLC now owns 820,411 shares of the biopharmaceutical company’s stock valued at $27,820,000 after acquiring an additional 117,700 shares during the period. Finally, Acadian Asset Management LLC increased its position in Emergent Biosolutions by 6.2% in the 4th quarter. Acadian Asset Management LLC now owns 1,445,412 shares of the biopharmaceutical company’s stock valued at $67,165,000 after acquiring an additional 84,713 shares during the period. Hedge funds and other institutional investors own 88.44% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Chardan Capital Boosts Emergent Biosolutions (EBS) Price Target to $53.00” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://theolympiareport.com/2018/01/20/chardan-capital-boosts-emergent-biosolutions-ebs-price-target-to-53-00.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.